🇺🇸 FDA
Pipeline program

Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

PRO-INF4-MA4002-JStz

Approved mab completed

Quick answer

Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine for Influenza and Pneumonia is a Approved program (mab) at SINOVAC BIOTECH LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
SINOVAC BIOTECH LTD
Indication
Influenza and Pneumonia
Phase
Approved
Modality
mab
Status
completed

Clinical trials